The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.
Pashtoon Murtaza Kasi, MD, MSc
Advertisement
Articles by Pashtoon Murtaza Kasi, MD, MSc
The novel search tool uses artificial intelligence to restructure trial information, making it easier for patients and providers to access clinical trial information.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
